
    
      This is a traditional 3+3 phase I trial design to identify the recommended phase II dose
      (RP2D) of Trabectedin [T] that can be used in combination with Doxorubicin [D] and Olaratumab
      [O] for the treatment of patients with advanced stage or recurrent LMS.

      Patients will be treated at an assigned dose level of combination therapy per dose escalation
      design.
    
  